Vertex began its research efforts for hepatitis C in 1993, and in May 2011, the U.S. Food and Drug Administration approved Vertex's first medicine, INCIVEK® (telaprevir), for the treatment of chronic hepatitis C genotype 1 infection in people with stable liver problems.

Founded more than 20 years ago in Cambridge, MA, Vertex now has ongoing worldwide research programs and sites in the U.S., U.K., and Canada. Today, Vertex has more than 2000 employees around the world, and Science magazine named Vertex No. 1 on its 2011 list of Top Employers in the life sciences.

To learn more about Vertex, visit our corporate website.